Marianna Dávid
University of Pécs
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marianna Dávid.
Genes, Chromosomes and Cancer | 2013
Donát Alpár; Danielle de Jong; Zsofia Holczer-Nagy; Béla Kajtár; Suvi Savola; Pál Jáksó; Marianna Dávid; Szabolcs Kosztolányi; László Kereskai; László Pajor; Karoly Szuhai
Multiple myeloma (MM) is a genetically heterogeneous disease with diverse clinical outcomes. Interphase fluorescence in situ hybridization (i‐FISH) is the most commonly used approach to detect recurrent cytogenetic abnormalities in this malignancy. We aimed to assess the performance of multiplex ligation‐dependent probe amplification (MLPA) to reveal copy number abnormalities (CNAs) in MM. Diagnostic bone marrow samples from 81 patients were analyzed using 42 MLPA probes for the following regions: 1p32‐31, 1p21, 1q21.3, 1q23.3, 5q31.3, 12p13.31, 13q14, 16q12, 16q23, and 17p13. All samples were also screened by i‐FISH for the presence of hyperdiploidy, deletion/monosomy of chromosome 13, deletion of TP53, disruption of the immunoglobulin heavy‐chain gene, t(4;14), t(11;14), t(14;16), t(8;14), gain of 5q and abnormalities of chromosome 1. A total of 245 alterations were detected in 79 cases (98%). Investigating the same aberrations, the two methods showed a congruency of higher than 90%. A low proportion of cells with the relevant abnormality, focal CNAs and unmatched probes were responsible for the discrepancies. MLPA revealed 95 CNAs not detected by i‐FISH providing additional information in 53 cases (65%). Scrutiny of CNAs on chromosome 1, using more than 20 probes, revealed significant heterogeneity in size and location, and variable intra‐chromosomal and intra‐clonal rates of loss or gain. Our results suggest that MLPA is a reliable high‐throughput technique to detect CNAs in MM. Since balanced aberrations are key to prognostic classification of this disease, MLPA and i‐FISH should be applied as complementary techniques in diagnostic pathology.
Pathology & Oncology Research | 2001
Timea Berki; Marianna Dávid; Beáta Bóné; Hajna Losonczy; János A. Vass; Péter Németh
The hypereosinophilic syndrome (HES) is a very rare disease, characterized by persistent eosinophilia with tissue involvement and organ dysfunction which often precedes a subsequent T cell lymphoma. Interleukin-5 secreted by a T lymphocyte subpopulation has been described in previous reports as the most important factor responsible for the prolonged lifespan of the eosinophils. The goal of the present study was to describe a fast, simple diagnostic method for the differentiation of HES and secondary eosinophilic states. Beside the surface marker analysis of peripheral blood mononu-clear cells (PBMC) we measured surface bound IgE molecules on lymphocytes and eosinophil cells, intracellular cytokines (IL-5, INFγ) in CD4+ lymphocytes and eosinophil major basic protein (MBP) in eosinophils using flow cytometric detection method. The appearance of an IL-5 producing cell population with a decreased number of INFγ positive lymphocytes was characteristic for the blood samples of HES patients. Predominance of Th2 cells with the appearance of a CD8+/CD3-/CD56+ cell population was restricted for the HES cases and could not be detected in secondary eosinophilic individuals. Our flow cytometric cytokine detection method (with parallel cell surface marker analysis) does not require cell separation or long term cell culture steps previously described for the detection of IL-5 producing cells. Therefore it seems to be a more appropriate approach for the differential diagnosis of primary and secondary eosinophilic states.
Blood | 2007
Marianna Dávid; Nicholas C.P. Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M. Goldman; Francis H. Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A. McArthur; Francois Xavier Mahon; Giorgio Massimini; Junia V. Melo; Philippe Rousselot; Robin Russell-Jones; John F. Seymour; Graeme N. Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F. Apperley
Seminars in Thrombosis and Hemostasis | 1991
Hajna Losonczy; Marianna Dávid; Ibolya Nagy
Orvosi Hetilap | 2010
Marianna Dávid; Hajna Losonczy; Miklós Udvardy; Z. Boda; György Blaskó; Attila Tar; György Pfliegler
Orvosi Hetilap | 2005
Orsolya Tóth; Marianna Dávid; Tamas Habon; Ágnes Nagy; Zsuzsanna Keszthelyi; Norbert Kovács; Hajna Losonczy
Orvosi Hetilap | 1989
K. Werling; I. Nagy; Hajna Losonczy; Marianna Dávid; Tamás Magyarlaki
Thrombosis Research | 2012
Réka Mózes; Orsolya Tóth; Hajna Losonczy; Marianna Dávid; Barbara Réger; Béla Melegh; Ágnes Nagy
Orvosi Hetilap | 2010
Marianna Dávid; Hajna Losonczy; Miklós Udvardy; Z. Boda; György Blaskó; Attila Tar; György Pfliegler
Orvosi Hetilap | 2010
Marianna Dávid; Hajna Losonczy; Miklós Udvardy; Z. Boda; György Blaskó; Attila Tar; György Pfliegler